Momentum: MACD histogram is negative (-0.00281) and negatively expanding → downside momentum is still building rather than stabilizing.
RSI(6): 16.13 (deep oversold) → bounce potential exists, but oversold alone is not a buy signal without trend/price stabilization.
Key levels: Immediate support S1 ~1.573 (price 1.52 is already below/pressuring this area); next support S2 ~1.365. Resistance/pivot overhead near 1.909, then 2.245.
Pattern-based forward look: Model suggests ~80% chance of -0.38% next day, +0.53% next week, +6.01% next month (near-term still weak; improvement bias is more medium-term).
Positive Catalysts
could trigger a reflex bounce if selling pressure exhausts.
Neutral/Negative Catalysts
No supportive news flow in the past week to explain/improve sentiment after the sharp selloff.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 4,175,000, +383.78% YoY (strong top-line growth off a low base).
Profitability: Net income -774,000 (still loss-making; down -11.64% YoY).
EPS: -1.75, -99.80% YoY (material deterioration in per-share earnings).
Gross margin: reported as 100 (flat YoY); this figure is unusual as presented and does not offset the ongoing net losses.
Overall: growth is visible in revenue, but earnings quality/profitability trend is negative, which weakens confidence in buying immediately after a breakdown.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating/target trend: becoming more cautious overall.
2026-01-08: Truist downgraded to Hold from Buy, PT cut to 222 from 231 (cites limited visibility, muted growth, margin pressure into 2026).
2026-01-09: Mizuho and Baird kept Outperform but trimmed PTs (216 from 225; 217 from 220).
2025-12-15: BofA downgraded to Neutral from Buy with PT cut (195 from 207).
2025-12-15: Barclays kept Equal Weight and raised PT to 200 from 185 (more constructive sector view).
Wall Street pros/cons view:
Pros: Several firms still see relative outperformance potential (Outperform ratings maintained by some).
Cons: Increasing emphasis on 2026 margin pressure, muted growth, and visibility issues; multiple downgrades/target cuts suggest expectations are being reset lower.
Note: The listed price targets (around ~$195–$222) appear inconsistent with the current trading price shown ($1.52), so analyst-target comparability to this ticker’s price should be treated cautiously based on the provided dataset.
People Also Watch
Wall Street analysts forecast ICON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICON is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ICON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICON is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.550
Low
2
Averages
2
High
2
Current: 1.550
Low
2
Averages
2
High
2
Mizuho
Outperform
to
NULL
downgrade
$225 -> $216
AI Analysis
2026-01-09
Reason
Mizuho
Price Target
$225 -> $216
AI Analysis
2026-01-09
downgrade
Outperform
to
NULL
Reason
Mizuho lowered the firm's price target on Icon to $216 from $225 and keeps an Outperform rating on the shares. The firm updated targets in the healthcare facilities and managed care group as part of a Q4 preview. Mizuho's physician survey indicated healthcare utilization growth trends decelerated sequentially despite easier year-over-year comps, which could indicate trend is peaking, the analyst tells investors in a research note.
Baird
Outperform -> Outperform
downgrade
$220 -> $217
2026-01-09
Reason
Baird
Price Target
$220 -> $217
2026-01-09
downgrade
Outperform -> Outperform
Reason
Baird lowered the firm's price target on Icon to $217 from $220 and keeps an Outperform rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ICON
